Last reviewed · How we verify
Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification
Approved treatments
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
- Gm-Csf · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification patent landscape — cliff calendar, originator estates, attackable patents
- Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification treatment landscape brief
- Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification treatment updates RSS
Frequently asked questions about Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification
What drugs treat Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification?
Tracked treatments include Gm-Csf.
What is the treatment for Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification?
Standard treatment for Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification includes Gm-Csf. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification patent cliff · Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification CI report
- Treatment: Gm-Csf · Pfizer
- Treatment: Gm-Csf · Pfizer
- Treatment: Gm-Csf · Pfizer
- Treatment: Gm-Csf · Pfizer
- Treatment: Gm-Csf · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing